Featured Research

from universities, journals, and other organizations

New Rheumatoid Arthritis Treatment Effective, Study Suggests

Date:
June 16, 2007
Source:
European League Against Rheumatism
Summary:
Nearly half -- 43.9 percent -- of rheumatoid arthritis patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50 percent improvement in symptoms at 24 weeks and more than one fifth achieved a 70 percent symptom improvement, according to new research.

Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a European study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. This study is the first phase III trial of tocilizumab.

Lead researcher Dr Josef Smolen of the Medical University of Vienna for Internal Medicine commented, "These data show the potential of tocilizumab as a novel and attractive approach to treating RA. The symptom improvements observed across both 4mg/kg and 8mg/kg doses show that tocilizumab offers significant promise to patients with moderate and severe RA."

Significant improvement in symptoms was observed in all patients receiving tocilizumab and methotrexate compared to placebo and methotrexate. At 24 weeks, an ACR70 (70% symptom improvement) was observed in 22%, an ACR50 (50% symptom improvement) in 43.9% and an ACR20 (20% symptom improvement) in 58.5% of patients receiving 8mg/kg tocilizumab plus methotrexate compared to placebo (2.0% p=<0.0001; 10.8% p=<0.0001 and 26.5% p=<0.0001 respectively). An ACR20 was equally noted in 47.9% of patients receiving 4mg/kg tocilizumab plus methotrexate compared to placebo (26.5% p=<0.0001).

A significantly higher proportion of patients treated with tocilizumab and methotrexate achieved a good/moderate EULAR response, observed in 79.5% of patients receiving tocilizumab 8mg/kg and 61.9% patients receiving 4mg/kg tocilizumab, versus 34.8% on placebo.

A reduction in Disease Activity Score (DAS28) was also observed from two weeks onwards in both tocilizumab groups, with a significant change from baseline to week 24 in patients treated with tocilizumab 8mg/kg (-3.43) and 4mg/kg (-2.68) compared to placebo (-1.55, p=0.0001).

The study involved 623 patients with sustained moderate to severe RA despite long standing treatment with methotrexate. Patients received 4mg/kg, 8mg/kg tocilizumab or placebo intravenously every four weeks for a period of 24 weeks. Patients were permitted concurrent treatment with methotrexate at their pre-study dose (10-25mg weekly). Treatment with all other disease modifying anti-rheumatic drugs (DMARDs) was discontinued at the beginning of the trial.

Tocilizumab is a novel humanised anti human interleukin 6 (IIL-6) receptor monoclonal antibody. IL-6 is a cytokine involved in the pathogenesis of RA and by targeted blockage of this receptor, tocilizumab slows down the progression of rheumatoid arthritis.

Adverse Events (AEs) were recorded throughout the duration of the trial with a similar AE profile reported in all three groups (8mg/kg, 4mg/kg and placebo). The AE profile of tocilizumab is consistent with data presented in previous studies with the treatment being generally well tolerated.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "New Rheumatoid Arthritis Treatment Effective, Study Suggests." ScienceDaily. ScienceDaily, 16 June 2007. <www.sciencedaily.com/releases/2007/06/070615094904.htm>.
European League Against Rheumatism. (2007, June 16). New Rheumatoid Arthritis Treatment Effective, Study Suggests. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2007/06/070615094904.htm
European League Against Rheumatism. "New Rheumatoid Arthritis Treatment Effective, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/06/070615094904.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins